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Figure S1. Lactate, glucose concentrations and pH levels measured on melanoma cell lines 
supernatants (SN–mel). Graphs show the concentration of lactate (black dots), glucose (red dots) (A) 
and the pH level (blue dots) (B) among different SN–mel and RPMI 1640 medium. 
 
Figure S2. Lactosis did not affect the viability of pDCs and T cells. pDCs and T cells purified from 
buffy coats of HD were cultured in RPMI 1640 medium supplemented with 10% FBS containing 
Sodium Lactate (10 mM; 15 mM; 20 mM) (n = 5, A–F) for 24 hours. 20 ng/ml IL–3 was added to pDCs 
culture. The cellular viability was analyzed by Annexin V/SYTOX AADvanced staining in flow 
cytometry. Aligned dot plot graphs show the percentages of dead (A, D), early apoptotic (B, E) and 
late apoptotic or necrotic cells (C, F). Bars represent the mean of biological replicates. The statistical 
significance was calculated by two–sample paired sign test.  
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Figure S3. BRAF and MEK inhibitors (BRAFi; MEKi) did not affect pDC viability and function. pDCs 
purified from buffy coats of HD were cultured in RPMI 1640 medium supplemented with 10% FBS 
and IL–3 (CTRL) and treated with BRAFi (PLX4032 1 µM) alone or in combination with MEKi (U0126 
12.5 µM). pDC viability was analyzed by Annexin V/SYTOX AADvanced staining in flow cytometry 
(n = 5) (A–C). Scatter dot plot graphs illustrate the percentage of dead (A), early apoptotic (B) or late 
apoptotic/necrotic cells (C); bars represent the mean with 95% CI (A–C). pDCs were stimulated with 
R848 and Imiquimod (IMQ) for 2 hours (D) and 6 hours (E) and with CpG–ODN 2216 for 6 hours (D, 
E). IFN–α (D) and CXCL10 (E) were analyzed by intracellular flow cytometry staining (n = 3). Scatter 
dot plot graphs show the percentage of positive pDCs evaluated on BDCA–2+/CD123+ cells; bars 
represent the mean with SD (D, E). The statistical significance was calculated by two–sample paired 
sign test.  
 
Figure S4. Gating strategy for the identification of peripheral blood immune populations. Flow 
cytometry analysis was performed on whole blood samples. The panels illustrate the gating strategy 
used to identify pDCs, mDCs, CD3+ and CD4+ T cells. At least 2x105 PBMCs were acquired according 
to the forward light scatter versus side light scatter profile and doublet discrimination was performed. 
Among CD14– cells, mDCs were recognized as CD45dim/ CD1c+/ CD4dim cells, whereas pDCs were 
BDCA–2+/CD123+. T lymphocytes were recognized as CD45+/CD3+/CD4+.
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Table S1. Clinical data of the Metastatic Melanoma (MM) cohort. 













#1 F 63 M1c Q61R wt NA No >3 72.0 PD Ipilimumab 
#2 F 53 M1c wt wt 155 * No >3 52.2 PD Ipilimumab 
#3 M 45 M1c wt V600E 230 * No <3 174.4 PR Vemurafenib 
#4 F 50 M1b wt V600E 154 * No <3 43.1 PR Vemurafenib 
#5 M 43 M1c wt V600E 318 * No >3 408.2 PR Dabrafenib + Trametinib 
#6 M 63 M1a wt V600K 152 * No <3 35.0 SD Vemurafenib 
#7 M 49 M1c wt V600E 433 ** No >3 227.9 PR Dabrafenib + Trametinib 
#8 M 67 M1c Q61R wt 286 * No <3 260.3 PD Ipilimumab 
#9 M 63 M1b wt V600E 230 * No <3 81.0 PR Dabrafenib + Trametinib 
#10 M 76 M1c Q61K wt 220 * Yes >3 137.1 PD Ipilimumab 
#11 M 64 M1c wt wt 558 * Yes >3 309.5 PD Ipilimumab 
#12 M 32 M1c wt V600E 160 * No >3 100.7 PR Dabrafenib + Trametinib 
#13 F 58 M1c Q61K wt 188 * No <3 8.0 PD Ipilimumab 
#14 M 50 M1b Q61R wt 247 * No <3 66.1 PD Ipilimumab 
#15 M 60 M1a wt wt 170 * No <3 83.3 PR Ipilimumab 
#16 M 67 M1c wt wt 320 * Yes >3 230.9 PD Ipilimumab 
#17 M 54 M1a Q61R wt 214 * No <3 77.9 PD Ipilimumab 
#18 M 48 M1c Q61R wt 1037 * Yes >3 209.5 PD Ipilimumab 
#19 M 62 M1c wt V600K 279 * Yes >3 389.9 PR Dabrafenib + Trametinib 
#20 M 79 M1b wt wt 181 * No >3 168.3 SD Ipilimumab 
#21 F 60 M1b wt V600E 227 * No <3 44.9 PR 
Vemurafenib + 
Cobimetinib 
#22 M 66 M1b wt V600K 199 * No <3 NA PD 
Vemurafenib + 
Cobimetinib 
#23 M 57 M1c wt V600E 1910 * No >3 165.1 SD Dabrafenib + Trametinib 
#24 M 23 M1c wt V600E 526 * Yes >3 293.6 PD Dabrafenib + Trametinib 
#25 F 43 M1a wt V600E 143 * No <3 0.0 SD Dabrafenib + Trametinib 
#26 M 61 M1b wt V600E 188 * No <3 56.3 SD Dabrafenib + Trametinib 
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#27 M 61 M1b wt wt NA No <3 104.5 PR Pembrolizumab 
#28 M 77 M1a wt V600E 121 * No <3 184.9 CR Dabrafenib + Trametinib 
#29 F 69 M1c wt V600K 184 * Yes <3 116.5 PD Dabrafenib 
NA = Not Assessable; LDH reference range: * (134 – 236 IU/L), ** (313 – 618 IU/L); CR = Complete Response; PR = Partial Response; SD = Stable Disease; PD = 
Progressive Disease. 
Table S2. Peripheral blood immune populations in the MM molecular groups at baseline (T0; N = 29). 
Immune Cell Population 
MM with BRAFV600+ 
(N = 16) 
MM with NRASQ61+  
(N = 7) 
MM BRAFwt/NRASwt  
(N = 6) 
N Median IQR N Median IQR N Median IQR p * 
n° leukocytes/µL 14 7350 6610–9660 5 8290 4930–9110 4 8040 6635–9315 0.9 
% neutrophils on LK 14 62.5 54.1–69 4 46.1 36.3–59.3 4 51.5 47.5–64.8 0.3 
% lymphocytes on LK 14 24.6 17–30.4 4 31.4 11.7–41.1 4 34.5 25.2–37.4 0.4 
% monocytes on LK 14 8.3 7.1–10.5 4 7 3.5–9.8 4 9.4 7.1–11.7 0.6 
% eosinophils on LK 14 2.1 0.5–2.5 4 1.4 0.7–2 4 1.7 1.1–3.9 0.6 
% basophils on LK 14 0.5 0.4–0.5 4 0.8 0.4–1 4 0.6 0.6–0.8 0.1 
% pDCs on PBMCs 16 0.3 0.2–0.3 7 0.2 0.1–0.5 6 0.2 0–0.3 0.6 
% mDCs on PBMCs 16 0.3 0.2–0.5 7 0.4 0.1–0.7 6 0.3 0.2–0.3 0.8 
% CD3+ on PBMCs 16 59.4 52.6–61.6 7 53.1 40.7–68.9 6 61.3 57.2–66.8 0.4 
% CD4+ on PBMCs 16 28.7 24.5–40.8 7 17.8 16.8–40.1 6 30.9 28.7–34.4 0.2 
% IFN–α+ pDCs 
R848 16 47.7 28.1–72.2 7 60.4 10.3–65 4 58.6 49.6–72.2 0.7 
IMQ 16 24.4 9.9–49 7 27 8.7–38.2 4 13.3 8.7–41.4 0.9 
CpG 14 9.8 4.1–14.5 7 9.3 6.3–10.6 5 9.3 5.4–11.7 0.9 
% CXCL10+ pDCs 
R848 13 81.8 71.9–85.8 7 80 4.8–85.2 4 74.5 62.7–76.1 0.3 
IMQ 13 48.8 46.4–61.8 7 45.7 14.7–61.2 4 34.8 21.4–55.3 0.5 
CpG 13 8.8 3.7–12.3 7 5.7 4.6–23.7 5 7.1 2.9–7.7 0.9 
IQR (interquartile range): Q1–Q3; LK: leukocytes; * p: p–value referred to comparison among the three different molecular groups of MM patients.
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Table S3. Analysis of the overall survival (OS) and the progression free survival (PFS) among MM 
patients (N = 29) during the follow–up. 
 
MM 
(N = 29) 
BRAFV600+ MM 
(N = 16) 
NRASQ61+ MM 
(N = 7) 
BRAFwt/NRAS
wt MM 
(N = 6) 
OS 
number (%) of deaths 18 (62) 10 (63) 6 (86) 2 (33) 
median time (months) 14 17 5 not reached 
survival at 12 months* (95% CI) 0.52 (0.33–0.68) 0.62 (0.35–0.81) 0.14 (0.01–0.46) 0.67 (0.19–0.90) 
PF
S 
number (%) of progressions** 22 (76) 10 (63) 7 (100) 5 (83) 
median time (months) 4 12 3 3 
survival at 12 months* (95% CI) 0.30 (0.15–0.47) 0.50 (0.25–0.71) – – 
*months from therapy initiation; **all deaths went into disease progression. 
Table S4. Univariate and multivariate Cox regression models for PFS in MM patients at baseline (T0; 
N = 29). 
Immune Cell Population 
Univariate Multivariate° 
HR p 95% CI HR p 95% CI 
n° leukocytes/µL 1.04** 0.51 0.93–1.15    
% neutrophils on LK 0.99 0.80 0.95–1.04    
% lymphocytes on LK 0.96 0.14 0.91–1.01    
% monocytes on LK 1.07 0.57 0.86–1.32    
% eosinophils on LK 0.75 0.18 0.49–1.14    
% basophils on LK 0.97* 0.76 0.79–1.19    
% pDCs on PBMCs 0.76* 0.08 0.56–1.04    
% mDCs on PBMCs 0.91* 0.45 0.03–4.42    
% CD3+ on PBMCs 0.97 0.14 0.93–1.01    
% CD4+ on PBMCs 0.95 0.02 0.91–0.99 0.98 0.6 0.94–1.04 
% IFN–α+ pDCs 
R848 0.99 0.31 0.97–1.01    
IMQ 0.99 0.26 0.97–1.01    
CpG 0.97 0.24 0.92–1.02    
% CXCL10+ 
pDCs 
R848 0.98 0.08 0.97–1.00    
IMQ 0.99 0.61 0.97–1.02    
CpG 1.02 0.24 0.99–1.04    
LK: leukocytes; *HR associated with a 0.1 unit increase; **HR associated with a 1000 unit increase; p: 
p–value; ºadjusted for molecular profile (NRASQ61+ vs BRAFV600+ or BRAFwt/NRASwt) and stage of the 
disease (M1c vs M1a or M1b). The significant p–values and relative hazard ratio are highlighted in 
bold. 
Table S5. Antibodies used for flow cytometry. 
Reagent Clone Conjugation Source 
Panel #1    
CD303 AC144 FITC Miltenyi Biotec 
CD123 AC145 VioBlue Miltenyi Biotec 
CD16 3G8 PE Becton Dickson 
CD8 HIT8a PerCP Cy5.5 Becton Dickson 
CD3 UCHT1 PE Cy7.7 Becton Dickson 
CD45RA 2D1 APC H7 Becton Dickson 
CD4 RPA–T4 V450 Becton Dickson 
CD1c  F10/21A3 PE Becton Dickson 
CD19 HIB19 FITC Becton Dickson 
CD14  M5E2 FITC Becton Dickson 
Panel #2    
CD303 AC144 FITC Miltenyi Biotec 
CD123 AC145 VioBlue Miltenyi Biotec 
IFN–α REA1013 APC Miltenyi Biotec 
CXCL10/IP–10 J034D6 PE Biolegend 
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